News Briefing channel feed

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

7 years ago

Equi­l­li­um's im­muno-in­flam­ma­to­ry drug wins FDA's or­phan drug sta­tus; Van­da sues FDA for man­dat­ing lengthy dog study

7 years ago

Split up the chair­man/CEO role at Al­ler­gan — ac­tivist in­vestor; Zo­genix files for FDA, EMA ap­proval of seizure drug

7 years ago

Am­gen, Sanofi back a round for re­al-world ev­i­dence plat­form tech; Dai­ichi Sanky­o's pex­i­dar­tinib se­cures speedy FDA re­view

7 years ago

Halozyme scores $30M in cash for its lat­est al­liance; Bernie Sanders takes aim at $375,000 rare dis­ease drug

7 years ago

EMA en­dors­es Teva's mi­graine drug; Dis­as­ter prone CTI Bio­Phar­ma re­scinds EU ap­pli­ca­tion for pa­cri­tinib

7 years ago

FDA stiff-arms Aveo on ti­vo, again; Sunovion Parkin­son's drug re­ject­ed

7 years ago

Pro­to­cols: No­var­tis CEO is still map­ping out San­doz's fu­ture; But Swiss gi­ant is gung ho on all things dig­i­tal

7 years ago

Aldeyra bags PhI­II-ready eye drug in He­lio buy­out; Liq­uid biop­sy mak­er On­co­Cyte shares sky­rock­et on val­i­da­tion da­ta

7 years ago

The FDA is back in busi­ness; Al­lo­gene giv­en the green sig­nal to test lym­phoma drug in hu­mans

7 years ago

Ab­b­Vie shares slide on slid­ing Hu­mi­ra rev­enue; Deer­field is mak­ing a big in­vest­ment in new de­vice star­tups

7 years ago

Rit­ux­an copy­cat pass­es first piv­otal test for Am­gen, Al­ler­gan; Iron­wood and biotech spin­out name new boards

7 years ago

RNAi leader Al­ny­lam inks col­lab­o­ra­tion pact with start­up; GV's Rosana Kapeller joins Schrödinger board

7 years ago

EC ex­pands ap­proval of Am­gen's Blin­cy­to; FDA gives uniQure green sig­nal to be­gin Hunt­ing­ton's study in hu­mans, Cy­to­ki­net­ics feed­back on SMA tri­al

7 years ago

Tyme flops on can­cer drug da­ta; Lil­ly IND fil­ing trig­gers $8M pay­ment to part­ner Zymeworks

7 years ago

Bay­er ax­ing 665 work­ers at US cam­pus; NASH biotech pumps up share price with an ‘in­ter­im’ snap­shot

7 years ago

As­traZeneca signs deal to pro­mote prod­uct made in Chi­na — in main­land Chi­na; Is­raeli deep brain stim­u­la­tion co Brain­sway sets stage for $30M Nas­daq IPO

7 years ago

Seres pro­motes CFO Er­ic Shaff to suc­ceed Pomer­antz as CEO; Ex­elix­is' Cabome­tyx bags US ap­proval for liv­er can­cer

7 years ago

FDA of­fers Pfiz­er pri­or­i­ty re­view for tafamidis; Clar­i­vate to merge with Churchill Cap­i­tal

7 years ago

CAN­bridge ex­pands rare dis­ease pact with WuXi Bi­o­log­ics; Watch for a man­u­fac­tur­ing site from Al­lo­gene

7 years ago

Roche names new Foun­da­tion Med chief; Ako­rn shares dip on FDA warn­ing let­ter; Zai Lab ad­vances piv­otal PARP study

7 years ago

Lil­ly to dis­play drug pric­ing in­fo on web­site; Catal­ent pledges $200M for its bi­o­log­ics unit

7 years ago

Pos­i­tive oc­u­lar im­plant da­ta bring Al­ler­gan one step clos­er to NDA; Vivek Ra­maswamy spawns an­oth­er 'Van­t'

7 years ago

Aim­mune en­ters in­to loan agree­ment with KKR; Boehringer bags rights to sec­ond RNAi drug from Dicer­na

7 years ago
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times